Key Highlights: U.S. FDA approval of Talicia ® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals , including investment of $36.3 million and exclusive rights to commercialize Aemcolo ® in the U.S. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...
RedHill plans to launch Talicia ® 1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Talicia ® is the first and only FDA approved rifabutin-based H. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...